Danish pharmaceutical group Lundbeck has won approval in the United States of its epilepsy drug, Sabril, to be used in children aged 10 years and older.
Lundbeck said in a statement the United States Food and Drug Administration (FDA) had approved Sabril as an add-on therapy for the treatment of refractory complex partial seizures in children who have inadequately responded to several other treatments.
© 2021 Thomson/Reuters. All rights reserved.